Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

833
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
833
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

590
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
590
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

591
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
591
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

266
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
266
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

497
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
497
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

426
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
426

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced broad-band intermuscular coherence in myoclonus: a targeted characterization study.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2026
Same author

Adaptive brain stimulation 2.0 for Parkinsonian gait.

Nature medicine·2026
Same author

Hand-Specific Engagement of Cerebello-Thalamo-Cortical and Higher-Order Sensorimotor Networks in Essential Tremor: Converging Evidence From GLM and MVPA-Based fMRI Analysis.

European journal of neurology·2026
Same author

Machine learning based EMG analysis of intermuscular coherence and cumulant density in tremor and myoclonus.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2026
Same author

Re-Emergent Tongue Tremor in Parkinson Disease.

Neurology·2026
Same author

The efficacy and safety of bilateral single-session ureteroscopy for bilateral urolithiasis: A systematic review.

Asian journal of urology·2026

Related Experiment Video

Updated: Sep 4, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.1K

Antiseizure Drugs and Movement Disorders.

Michel Sáenz-Farret1, Marina A J Tijssen2,3, Dawn Eliashiv4

  • 1Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Division of Neurology, University of Toronto, 399 Bathurst St, Toronto, ON, M5T 2S8, Canada.

CNS Drugs
|July 21, 2022
PubMed
Summary
This summary is machine-generated.

Antiseizure drugs can treat or cause movement disorders like tremor and parkinsonism. This review details which drugs affect movement disorders, aiding treatment choices for patients with epilepsy and movement issues.

More Related Videos

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy
08:26

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Published on: October 19, 2021

5.8K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.8K

Related Experiment Videos

Last Updated: Sep 4, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.1K
Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy
08:26

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Published on: October 19, 2021

5.8K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.8K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • The interplay between antiseizure drugs (ASDs) and movement disorders is complex and under-reviewed.
  • ASDs are commonly used to treat movement disorders, but evidence varies.
  • ASDs can also induce iatrogenic movement disorders, such as parkinsonism and tremor.

Purpose of the Study:

  • To systematically review the literature on the use of ASDs for treating movement disorders.
  • To identify ASDs that may worsen or induce movement disorders.
  • To summarize proposed mechanisms and risk factors in ASD-movement disorder interactions.

Main Methods:

  • Conducted a comprehensive literature search.
  • Examined combinations of 15 movement disorders and 24 ASDs.
  • Focused on movement disorders treated, worsened, or induced by ASDs.

Main Results:

  • Clonazepam, gabapentin, lacosamide, levetiracetam, oxcarbazepine, perampanel, phenobarbital, pregabalin, primidone, topiramate, and zonisamide are commonly used to treat movement disorders.
  • Cenobamate, ethosuximide, felbamate, lamotrigine, phenytoin, tiagabine, and vigabatrin can worsen or induce movement disorders.
  • Carbamazepine and valproate have variable effects; brivaracetam, eslicarbazepine, lacosamide, and stiripentol show no reported effect.

Conclusions:

  • Evidence guides ASD selection for patients with co-occurring epilepsy and movement disorders.
  • Understanding these interactions improves knowledge of movement disorder pathophysiology and treatment.
  • Further research is needed on newer ASDs' effects on movement disorders.